The Adult Hematopoietic Stem Cell Transplantation Fellowship Program at Memorial Sloan Kettering Cancer Center is an independent, one-year program designed to prepare physicians for academic careers in Stem Cell Transplantation, including experience with clinical research.
The Bone Marrow Transplantation Program at MSK was founded in 1973 and is one of the largest in the country. The Program performs over 400 new cases per year and includes transplants using autologous grafts, grafts from matched and mismatched related or volunteer donors, and umbilical cord blood, ablative and non-ablative conditioning regimens, conventional and CD34-selected (T-cell depleted) grafts, and adoptive cell therapy protocols with specific T cells or NK cells.
The Fellowship provides training in inpatient and outpatient settings, with a specific focus on the different subspecialties within Hematopoietic Stem Cell Transplantation, as well as exposure to the different disciplines that relate to Hematopoietic Stem Cell Transplantation. These include Radiation Oncology, and clinical laboratory rotations.
Fellows will also have opportunities to participate in ongoing research projects or initiate an independent project. This process will be helped by the assigning of a mentor throughout the fellowship, who will ensure that the objectives of the fellow are met for the training year.
The program includes a wide variety of conferences that complement the clinical aspects. These are based on a disease management concept and will group physicians from different specialties who treat the disease in question. In addition to these patient-based conferences, a weekly research meeting is held.
March 1st of the preceding year.
Length of Program
Board-eligible or board-certified graduates of an accredited US Hematology/Oncology fellowship program or equivalent.
Number of Positions
How to Apply
Please send an updated CV and personal statement to David Chung, MD, PhD at the address below. Three letters of recommendation should also be sent directly to Dr. Chung.